Actively Recruiting
SIRT for Potentially Resectable HCC
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2023-09-14
35
Participants Needed
1
Research Sites
182 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is conducted to evaluate the efficacy and safety of Y-90 selective internal radiation therapy (SIRT) in patients with potentially resectable hepatocellular carcinoma (HCC).
CONDITIONS
Official Title
SIRT for Potentially Resectable HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- HCC with diagnosis confirmed pathologically or clinically
- No previous treatment for HCC
- At least one measurable intrahepatic target lesion
- Potentially resectable HCC: tumor(s) confined to the left or right hemiliver, with or without invasion to the unilateral branch of the portal vein and/or hepatic vein
- Disease amenable to SIRT after evaluation
- Child-Pugh Class A or without cirrhosis
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Patients with active hepatitis B allowed if receiving antiviral treatment to achieve HBV DNA <10^3 IU/mL
- Patients with hepatitis C must have completed anti-HCV treatment
- Adequate organ and bone marrow function, including specified blood counts and liver/kidney function tests
- Life expectancy of at least 6 months
You will not qualify if you...
- Tumor involving main portal vein, bilateral branches of portal vein, or vena cava
- Tumor extension beyond one lobe of the liver
- Bilobar tumor distribution
- Extrahepatic metastasis
- Decompensated liver function, including ascites, bleeding from esophageal and gastric varices, and/or hepatic encephalopathy
- Organ dysfunction (heart or kidney)
- Positive for both HBsAg and anti-HCV antibody concurrently
- History of malignancy other than HCC
- Uncontrolled infection
- History of HIV
- History of organ or cell transplantation
- Patients with bleeding tendency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 510260
Actively Recruiting
Research Team
M
Mingyue Cai, Dr.
CONTACT
K
Kangshun Zhu, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here